Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Mem. Inst. Oswaldo Cruz ; 108(4): 438-445, jun. 2013. tab, graf
Artículo en Inglés | LILACS | ID: lil-678277

RESUMEN

Leptospirosis in humans usually involves hypokalaemia and hypomagnesaemia and the putative mechanism underlying such ionic imbalances may be related to nitric oxide (NO) production. We previously demonstrated the correlation between serum levels of NO and the severity of renal disease in patients with severe leptospirosis. Methylene blue inhibits soluble guanylyl cyclase (downstream of the action of any NO synthase isoforms) and was recently reported to have beneficial effects on clinical and experimental sepsis. We investigated the occurrence of serum ionic changes in experimental leptospirosis at various time points (4, 8, 16 and 28 days) in a hamster model. We also determined the effect of methylene blue treatment when administered as an adjuvant therapy, combined with late initiation of standard antibiotic (ampicillin) treatment. Hypokalaemia was not reproduced in this model: all of the groups developed increased levels of serum potassium (K). Furthermore, hypermagnesaemia, rather than magnesium (Mg) depletion, was observed in this hamster model of acute infection. These findings may be associated with an accelerated progression to acute renal failure. Adjuvant treatment with methylene blue had no effect on survival or serum Mg and K levels during acute-phase leptospirosis in hamsters. .


Asunto(s)
Animales , Cricetinae , Canales Iónicos/sangre , Leptospirosis/tratamiento farmacológico , Azul de Metileno/uso terapéutico , Modelos Animales de Enfermedad , Guanilato Ciclasa/efectos de los fármacos , Leptospirosis/sangre , Magnesio/sangre , Óxidos de Nitrógeno/sangre , Potasio/sangre , Receptores Citoplasmáticos y Nucleares/efectos de los fármacos , Sodio/sangre
2.
Experimental & Molecular Medicine ; : 347-352, 2002.
Artículo en Inglés | WPRIM | ID: wpr-203702

RESUMEN

Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, is known to inhibit osteoclastogenesis by acting as a soluble decoy receptor for the receptor activator of NF-kB ligand (RANKL). We report the presence of OPG on the membrane of osteoclasts and the possibility of the direct action of OPG on them. Highly pure osteoclast precursors were isolated from mouse long bones and induced to differentiate into mature osteoclasts by M-CSF and soluble RANKL (sRANKL). The presence of OPG on the membrane of these cells was confirmed by western blotting and immunostaining. Furthermore, sRANKL was found to be bound to the OPG on the osteoclast precursors. These results suggest that OPG might have a new role during the differentiation of osteoclasts beyond its role as a soluble decoy receptor. The mechanism of the existence of OPG on osteoclast precursors remains to be found.


Asunto(s)
Animales , Ratones , Huesos/citología , Proteínas Portadoras/inmunología , Diferenciación Celular/efectos de los fármacos , Membrana Celular/metabolismo , Células Cultivadas , Glicoproteínas/efectos de los fármacos , Factor Estimulante de Colonias de Macrófagos/farmacología , Glicoproteínas de Membrana/inmunología , Ratones Endogámicos ICR , Osteoclastos/efectos de los fármacos , Receptores Citoplasmáticos y Nucleares/efectos de los fármacos , Células Madre/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA